Please note that this was recorded in 2017. All AMPEDTM content is reviewed and approved annually by the Training & Education Committee as relevant and accurate, but new data may now be available and new studies may have since been published.
AMP Education is constantly updating these educational offerings, so keep checking back at educate.amp.org for new content, content updates, and information on cutting-edge molecular pathology research and applications.
Description:
In an era of routine high throughput medical and tumor exome sequencing, putative drivers may be readily identified but functional annotation is often lacking and ultimately the genetic underpinnings of many diseases left uncertain. Forward genetic screens evaluate a large number of genomic targets for their relevance to a specific phenotype and recent technological advances permit total gene knockdown that can be applied across many thousands of genes. Sequence-specific programmable nucleases such as CRISPR-Cas9 enable targeted modification of the DNA itself; CRISPR technologies employed with guide RNA libraries can permit genome-scale screening to identify novel mechanisms of phenotypic abnormalities in constitutional and somatic contexts. Directed applications, including in-patient derived cell models, allow for exploration of mechanisms of drug resistance and identification of novel functional elements in the noncoding genome and epigenome.
Genome Editing with CRISPR-Cas Nucleases
J. Keith Joung, MD, PhD, Massachusetts General Hospital, Charlestown, MA, USA
Accelerating Prediction of Tumor Vulnerabilities Using Next-generation Cancer Models
Jesse S. Boehm, PhD, Broad Institute, Cambridge, MA, USA
Learning Objectives:
- Explore the activities and specificities of CRISPR nucleases and the implications for clinical applications.
- Describe how CRISPR screens can identify novel regulatory sites in the genome and epigenome relevant to cancer evolution and chemotherapy resistance.
- Identify applications of genome editing in human cancers using patient-derived cell models for exploration of signaling networks and novel therapeutic targets.
Duration: 1.50 hr
Recording Date: November 18, 2017
Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
